Second, with the advent of angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i), patients have experienced significant improvement in the treatment of heart failure compared with previous ones (15). Here, SLC5A2 is linked to heart failure.